Virid­i­an tar­gets Hori­zon's Te­pez­za with chron­ic thy­roid eye dis­ease da­ta, set­ting up the biotech for its sec­ond PhI­II

Virid­i­an Ther­a­peu­tics said its IV-ad­min­is­tered an­ti­body led to clin­i­cal im­prove­ments in a small group of pa­tients with the chron­ic form of thy­roid eye dis­ease, as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER